Lucence promotes lung cancer research at ASCO 2022

LabPulse.com staff writers
May 31, 2022
2022 01 10 23 10 0651 Lab Test Tube Dna Blood 400

Oncology company Lucence is directing attention to research presentations involving its amplification-based next-generation sequencing (NGS) technology at this week’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

In three separate poster presentations, Lucence will share data showing how a total nucleic acid approach combining circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) in one liquid biopsy test could increase actionable molecular information in lung cancer patients, according to the company.

Latest in Lung Cancer
Lung Cancer2 Social
Micronoma receives FDA breakthrough device designation for liquid biopsy assay to detect lung carcinoma
January 11, 2023
Lung Cancer Social
Argus Research initiates coverage of BioAffinity Technologies at $9 per share
December 19, 2022
Lung Cancer Hotspot Social
University of Louisville developing experimental approach for lung cancer breath test
December 2, 2022
Cancer Lung Social
Chest publication suggests potential for MagArray blood test to stratify lung cancer risk
November 21, 2022
Related Stories
2020 01 08 00 29 4037 Colon Cancer 400
Clinical Utility
ASCO presentation highlights clinical utility of ctDNA testing
2021 12 01 16 11 2152 Lab Blood Dropper V2 400
Cancer
GTC to present liquid biopsy testing approach at ASCO 2022
2022 01 10 23 10 0651 Lab Test Tube Dna Blood 400
HBV
Lucence promotes study of LiquidHallmark biopsy assay
2022 01 10 23 10 0651 Lab Test Tube Dna Blood 400
Small Cell Lung Cancer
Lucence offers expanded cfRNA version LiquidHallmark
More in Lung Cancer
Micronoma receives FDA breakthrough device designation for liquid biopsy assay to detect lung carcinoma
The company noted that as a result of the designation, it can expect continued guidance and prioritized reviews from the agency of an upcoming clinical trial, part of a process aimed at obtaining a pre-market approval.
January 11, 2023
Lung Cancer2 Social
Argus Research initiates coverage of BioAffinity Technologies at $9 per share
BioAffinity's CyPath Lung lab-developed test uses flow cytometry and machine-learning algorithms to profile the approximately 20 million cells in an average sputum sample in less than 20 minutes.
December 19, 2022
Lung Cancer Social
University of Louisville developing experimental approach for lung cancer breath test
A research group is leveraging measurements of volatile organic compounds and machine learning to develop a test that detects lung cancer.
December 2, 2022
Lung Cancer Hotspot Social
Chest publication suggests potential for MagArray blood test to stratify lung cancer risk
Its Knodule ID test is a multianalyte assay with algorithmic analysis comprising seven protein biomarkers and six clinical factors.
November 21, 2022
Cancer Lung Social
Biofidelity developing assay for single-molecule detection of multiple gene fusions
The firm said its assay analyzes DNA and RNA concurrently from a single patient sample and can return results within two days.
October 18, 2022
Lung Cancer2 Social
Delfi tapped for European lung cancer screening study
The trial will explore how often people should get screened for lung cancer if their initial CT exam is negative; Delfi's liquid biopsy testing will help investigators assess whether study participants could benefit from a screening CT exam. The trial is being conducted via a partnership with the Netherlands Cancer Institute (NKI) and the institute for DiagNostic Accuracy (iDNA). Delfi will work with the first 9,000 study participants enrolled in the trial through the NKI and Gustave Roussy in Villejuif, France, it said.
September 11, 2022
2022 08 08 21 26 6857 Lung Cancer2 400
Most Popular
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for unnecessary urinalysis testing
Quest Diagnostics offers suite of services for transplant patients and living donors
Simple blood test can detect PTSD biomarkers
Rapid nirmatrelvir treatment in study reduced long-COVID risk
Illumina NGS software to enable tertiary analysis for oncology, rare disease
Serum protein in study predicted which patients might die without a liver transplant
More in Lung Cancer
OncoCyte nabs five-year supply contract for lung cancer test
A molecular stratification test, DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy.
August 30, 2022
2022 08 08 21 26 6857 Lung Cancer2 400
Guardant expands use of liquid biopsy test to breast, lung cancer
Guardant Reveal identifies circulating tumor DNA in blood as soon as three weeks after surgery and eliminates the need for a tissue biopsy, the company said.
August 14, 2022
2019 04 24 18 42 4242 Dna Blue 400
Gene analysis sees success in cancer treatment study
In research presented Sunday at the International Association for the Study of Lung Cancer (IASLC) meeting in Vienna, a team led by Dr. Kei Morikawa of St. Marianna University School of Medicine in Kawasaki, Japan, has found that gene analysis using cytological specimens had a high success rate and that the yield and quality of extracted nucleic acid were adequate for panel analysis.
August 7, 2022
2022 08 08 21 26 6857 Lung Cancer2 400
Guardant Health highlights clinical results at IASLC
A study that used Guardant's GuardantInform database analyzed information from more than 2,000 patients with any EGFR mutation who had undergone osimertinib therapy, as well as outcomes from this therapy up to five years after it began. It showed a 12.5% incidence of the mutation in lung cancer patients unlikely to respond to the treatment, the company said.
August 7, 2022
2020 06 01 18 51 2022 Cancer Lung 400
Foundation Medicine highlights lung cancer study results
The findings are from the Prospective Clinicogenomic (PCG) study and were published August 5 in the Journal of Thoracic Oncology Clinical and Research Reports.
August 7, 2022
2021 11 10 18 26 8156 Science Genome Sequence Dna Map 400
Biodesix touts VeriStrat test results
The blood-based test was predictive of progression-free survival and overall survival in patients with non-small cell lung cancer with low or negative PD-L1 treated with immune checkpoint inhibitors, the firm said.
July 19, 2022
2019 09 09 20 46 2283 Lung Cancer 400
Page 1 of 6
Next Page